Khảo sát tỉ lệ sử dụng kháng đông kéo dài trên bệnh nhân thuyên tắc huyết khối tĩnh mạch điều trị ngoại trú

This study was conducted to evaluate the rate of patients receiving anticoagulation therapy for more than 3 months among outpatients with venous thromboembolism treated at University Medical Center Ho Chi Minh City, Vietnam. Subjects: Outpatients with venous thromboembolism treated at University Medical Center Ho Chi Minh City from January 2022 to December 2023. Study design: A retrospective, cross-sectional descriptive study. Results: A total of 220 patients met the inclusion criteria, with a mean age of 63.8 ± 16.4 years, and a female-to-male ratio of 1.9:1. The most common comorbidities were hypertension (52.7%), obesity (32.3%), diabetes (29.1%), and cancer (14.1%). Additionally, 18.2% of patients had right ventricular dysfunction on echocardiography. Most patients were on extended anticoagulation therapy (> 3 months), accounting for 93.2%. Of these, 33.6% were treated for 3–6 months, 29.8% for 6–12 months, and 36.6% for more than 12 months. Among those treated for up to 3 months, DOACs (direct oral anticoagulants) were predominant at 80%, followed by VKA (vitamin K antagonists) at 13.3%, and Enoxaparin at 6.7%. For those treated beyond 3 months, DOACs were used in 88.3%, while VKAs accounted for 11.7%. Conclusion: The study showed that most outpatients with venous thromboembolism were prescribed extended anticoagulation therapy (> 3 months), with DOACs being the most commonly used drugs.